TY - JOUR
T1 - CYD-TDV dengue vaccine
T2 - Systematic review and meta-analysis of efficacy, immunogenicity and safety
AU - Godói, Isabella Piassi
AU - Lemos, Livia Lovato Pires
AU - De Araújo, Vânia Eloisa
AU - Bonoto, Braúlio Cesar
AU - Godman, Brian
AU - Guerra Júnior, Augusto Afonso
N1 - Publisher Copyright:
© 2017 Future Medicine Ltd.
PY - 2017/3
Y1 - 2017/3
N2 - Introduction: Dengue virus (DENV) is a serious global health problem. CYD-TDC (Dengvaxia®) was the first vaccine to gain regulatory approval to try and address this problem. Aim: Summarize all available evidence on the immunogenicity, efficacy and safety of the CYD-TDV dengue vaccine. Method: Meta-analysis and systematic review. Results: The best and worst immunogenicity results were for DENV4 and DENV1, respectively. Vaccine efficacy of 60% was derived from studies with participants aged 2-16 years old, with DENV4 and DENV2 presenting the best and worst results, respectively. Erythema and swelling were more frequent with CYD-TDV. No differences were detected for systemic adverse events. Conclusion: CYD-TDV showed moderate efficacy in children and adolescents. From the immunogenicity results in adults, we can expect satisfactory efficacy from vaccination in this population.
AB - Introduction: Dengue virus (DENV) is a serious global health problem. CYD-TDC (Dengvaxia®) was the first vaccine to gain regulatory approval to try and address this problem. Aim: Summarize all available evidence on the immunogenicity, efficacy and safety of the CYD-TDV dengue vaccine. Method: Meta-analysis and systematic review. Results: The best and worst immunogenicity results were for DENV4 and DENV1, respectively. Vaccine efficacy of 60% was derived from studies with participants aged 2-16 years old, with DENV4 and DENV2 presenting the best and worst results, respectively. Erythema and swelling were more frequent with CYD-TDV. No differences were detected for systemic adverse events. Conclusion: CYD-TDV showed moderate efficacy in children and adolescents. From the immunogenicity results in adults, we can expect satisfactory efficacy from vaccination in this population.
KW - CYD-TDV
KW - dengue
KW - meta-analysis
KW - systematic review
KW - vaccines
UR - http://www.scopus.com/inward/record.url?scp=85011629651&partnerID=8YFLogxK
U2 - 10.2217/cer-2016-0045
DO - 10.2217/cer-2016-0045
M3 - Review article
C2 - 28084784
AN - SCOPUS:85011629651
SN - 2042-6305
VL - 6
SP - 165
EP - 180
JO - Journal of Comparative Effectiveness Research
JF - Journal of Comparative Effectiveness Research
IS - 2
ER -
